| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
344,673 | 189,951 | 89,441 | 55,529 | 7,559 | ||
General and administrative | ||||||
134,449 | 34,603 | 18,141 | 5,109 | 2,137 | ||
Total operating expenses | ||||||
479,122 | 224,554 | 107,582 | 60,638 | 9,696 | ||
Loss from operations | ||||||
-479,122 | -224,554 | -107,582 | -60,638 | -9,696 | ||
Other income (expense): | ||||||
Non-cash interest expense on mandatorily redeemable preferred shares | ||||||
12,711 | 0 | 0 | - | - | ||
Interest expense | ||||||
- | - | - | 385 | - | ||
Non-cash interest expense on liability related to sale of future royalties | ||||||
26,580 | 11,726 | 0 | 0 | - | ||
Change in fair value of warrant liability | ||||||
0 | 1,182 | 3,241 | -154 | - | ||
Change in fair value of derivative liability | ||||||
3,875 | 0 | -512 | 65 | 370 | ||
Change in fair value of contingent equity liability | ||||||
0 | 0 | 13,082 | 2,263 | - | ||
Loss from equity method investment | ||||||
-6,076 | -2,808 | -1,885 | -247 | - | ||
Other | ||||||
-22 | -185 | -906 | 0 | -370 | ||
Total other expense, net | ||||||
-49,264 | -15,901 | -18,602 | -2,806 | - | ||
Loss before provision for income taxes | ||||||
-528,386 | -240,455 | -126,184 | -63,444 | -10,066 | ||
Provision for income taxes | ||||||
419 | 467 | 1,006 | 90 | - | ||
Net loss and comprehensive loss | ||||||
-528,805 | -240,922 | -127,190 | -63,534 | -10,066 | ||
Net loss attributable to non-controlling interests | ||||||
- | - | - | 143 | 4 | ||
Accretion of beneficial conversion feature on Series A preferred shares | ||||||
0 | 0 | 12,006 | 0 | - | ||
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. | ||||||
-528,805 | -240,922 | -139,196 | -63,677 | -10,062 | ||
Net loss per share - basic and diluted (in dollars per share) | ||||||
-10.91 | -6.15 | -5.00 | -5.05 | -0.91 | ||
Weighted average common shares outstanding - basic and diluted (shares) | ||||||
48,489 | 39,188 | 27,845 | 12,608 | 11,009 | ||